According to Sinopharm Hyundai's announcement, the company has received the “Drug Registration Certificate” for voglibose tablets approved and issued by the State Drug Administration. The specifications are 0.2 mg and 0.3 mg, and the registration classification is classified as 4 types of chemicals, which is considered to have passed the consistency evaluation. Votribose tablets are oral hypoglycemic agents used to improve postprandial hyperglycemia in patients with type 2 diabetes. In 2025, the sales volume of the drug in public medical institutions and urban pharmacies across the country was 200 million yuan. The company invested a total of 13.347,900 yuan in R&D for this project. This certification to expand the company's product range in the field of endocrine and metabolic treatment will not have a significant impact on current business performance, and there is uncertainty about drug sales.

According to Sinopharm Hyundai's announcement, the company has received the “Drug Registration Certificate” for voglibose tablets approved and issued by the State Drug Administration. The specifications are 0.2 mg and 0.3 mg, and the registration classification is classified as 4 types of chemicals, which is considered to have passed the consistency evaluation. Votribose tablets are oral hypoglycemic agents used to improve postprandial hyperglycemia in patients with type 2 diabetes. In 2025, the sales volume of the drug in public medical institutions and urban pharmacies across the country was 200 million yuan. The company invested a total of 13.347,900 yuan in R&D for this project. This certification to expand the company's product range in the field of endocrine and metabolic treatment will not have a significant impact on current business performance, and there is uncertainty about drug sales.